STOCK TITAN

Lisata Therapeutics to Present at NobleCon19 Investor Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Lisata Therapeutics, Inc. (Nasdaq: LSTA) announced that David J. Mazzo, PhD, President and CEO, will present at NobleCon19, Noble Capital Markets’ Nineteenth Annual Emerging Growth Equity Conference, on December 4, 2023. The company is developing innovative therapies for advanced solid tumors and serious diseases.
Positive
  • None.
Negative
  • None.

BASKING RIDGE, N.J., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that David J. Mazzo, PhD, President and Chief Executive Officer of Lisata, will present at NobleCon19, Noble Capital Markets’ Nineteenth Annual Emerging Growth Equity Conference, being held December 3-5, 2023 at Florida Atlantic University, Executive Education Complex, in Boca Raton, FL.    

Dr. Mazzo’s presentation will be held on Monday, December 4, 2023 at 10:00am Eastern time in Presentation Room 4. Management will also host 1x1 meetings with investors at the conference on Monday, December 4, 2023. Investors can register to attend at website: noblecon19.com.

About Lisata Therapeutics

Lisata Therapeutics is a clinical-stage pharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. Lisata’s lead product candidate, LSTA1, is an investigational drug designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to target and penetrate solid tumors more effectively. Based on Lisata’s CendR Platform® Technology, Lisata has already established noteworthy commercial and R&D partnerships. The Company expects to announce numerous clinical study and business milestones over the next two years and has projected that its current business and development plan is funded with available capital through these milestones and into early 2026. For more information on the Company, please visit www.lisata.com.

Contact:

Investors and Media:

Lisata Therapeutics, Inc.
John Menditto
Vice President, Investor Relations and Corporate Communications
Phone: 908-842-0084
Email: jmenditto@lisata.com


FAQ

What is the company name and ticker symbol for Lisata Therapeutics?

The company name is Lisata Therapeutics, and the ticker symbol is LSTA.

When and where will David J. Mazzo, PhD, present at NobleCon19?

Dr. Mazzo will present on December 4, 2023, at Florida Atlantic University, Executive Education Complex, in Boca Raton, FL.

What type of therapies is Lisata Therapeutics developing?

Lisata Therapeutics is developing innovative therapies for the treatment of advanced solid tumors and other serious diseases.

How can investors register to attend NobleCon19?

Investors can register to attend at the website noblecon19.com.

Lisata Therapeutics, Inc.

NASDAQ:LSTA

LSTA Rankings

LSTA Latest News

LSTA Stock Data

23.67M
6.75M
19%
8.93%
0.2%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States of America
BASKING RIDGE

About LSTA

caladrius biosciences, inc., a clinical-stage biopharmaceutical company, develops cellular therapeutic product candidates to address diseases and conditions caused by ischemia. its product candidates include developmental treatments for cardiovascular diseases, such as clbs12 for the treatment of critical limb ischemia; clbs16, which is in phase ii clinical trial for the treatment of coronary microvascular dysfunction; clbs14, a regenerative medicine advanced therapy for treating no-option refractory disabling angina. the company was formerly known as neostem, inc. and changed its name to caladrius biosciences, inc. in june 2015. caladrius biosciences, inc. was founded in 1980 and is headquartered in basking ridge, new jersey.